Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2026-03-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于签署日常关联交易协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of routine related-party transaction agreements by the company. It details the nature of the transactions, the parties involved, pricing, contract terms, and the board's approval process. It explicitly states that the transactions are routine, comply with regulations, and do not require shareholder meeting approval. There are no financial statements or comprehensive financial data presented, nor is this a transcript, presentation, or report. The document is a formal announcement of a corporate action related to related-party transactions, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Interim Report, or Capital Update. The document length (9252 characters) is sufficient for a detailed announcement but does not contain financial statements or audit information to classify as a report type.
2026-03-02 Chinese
2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a '2025年度业绩快报公告' which translates to '2025 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2025, including revenue, profit, and earnings per share, but explicitly states that the data is unaudited and preliminary, and that the final audited data will be in the 2025 Annual Report. The document length is 1702 characters, which is relatively short and the text emphasizes that the full audited report is forthcoming. This matches the characteristics of an Earnings Release (ER) or a preliminary earnings announcement rather than a full Annual Report (10-K). It is not a report publication announcement (RPA) because it contains substantive preliminary financial data, not just a notice of report availability. Therefore, the best classification is Earnings Release (ER). FY 2025
2026-02-27 Chinese
自愿披露关于GB19注射液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about receiving approval from the National Medical Products Administration (国家药监局) for clinical trials of a new drug (GB19 injection). It details the approval notice, drug information, and potential impact on the company. The document is short (1227 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval event related to drug development, not a financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit other specific categories.
2026-02-25 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 科兴生物制药股份有限公司 regarding the progress of its share repurchase program through centralized bidding transactions. It includes details such as the repurchase plan, amounts, prices, and progress updates as of January 31, 2026. The document does not contain financial statements or detailed financial analysis but reports on the company's share buyback activity and compliance with regulatory requirements. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares. The document length is 1737 characters, which is consistent with an announcement rather than a full financial report.
2026-02-03 Chinese
2025年年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2025 年年度业绩预告' which translates to '2025 Annual Performance Forecast'. It provides preliminary profit estimates for the full fiscal year 2025, including net profit attributable to the parent company and net profit excluding non-recurring items. It explicitly states that the forecast is unaudited and based on preliminary calculations by the company's finance department. The document also includes a risk warning about the forecast's uncertainty and notes that the final audited annual report will be published later. The document length is short (1163 characters) and it is clearly a performance forecast announcement, not a full annual report or audited financial statement. This fits the definition of an Earnings Release (ER) as it is an initial announcement of yearly financial results highlights, not the full annual report (10-K) or audit report (AR). FY 2025
2026-01-30 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 科兴生物制药股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, and references previous announcements about the repurchase plan and price adjustments. The document does not contain financial statements or detailed financial analysis but focuses on the status and details of the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2026-01-04 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.